Why this might matter to you
If you carry the APOE e4/e4 genotype, you have probably already been pummeled with "Alzheimer's" and "Dementia" related concerns. While this genotype is meaningful and deserves thoughtful lifestyle consideration, it is also worth slowing down to consider what APOE is in the first place. APOE is a gene involved in how your body moves cholesterol and lipids around, including in the brain, and it comes in three common versions: e2, e3, and e4. Two copies of e4 is the configuration most strongly associated with late-onset Alzheimer's disease in the published literature. That association is real and well replicated. It is also a population-level risk, not a diagnosis, and not a verdict about you specifically.
Here is roughly how common each APOE genotype is in people of European descent. These figures are approximate and vary by population and region; they are consistent with the Farrer et al. (1997) meta-analysis and standard population data PMID 9343467:
- e3/e3: about 60 percent, the common reference genotype
- e3/e4: about 20 to 25 percent
- e2/e3: about 11 to 13 percent
- e4/e4: about 2 to 3 percent
- e2/e4: about 2 percent
- e2/e2: about 1 percent
(e2/e3 and e3/e2 are the same genotype, so they are counted together. e4 also becomes more common at higher latitudes within Europe, which is part of why these numbers shift between studies.)
What it does and doesn't change
An e4/e4 genotype raises your statistical risk of late-onset Alzheimer's disease relative to the most common e3/e3 genotype, by enough that it is the single most studied common genetic risk factor for the disease. That being said, an e4/e4 genotype does not decide the outcome. Many people with two copies of e4 never develop Alzheimer's, and many people without it do. The published risk estimates come mostly from European-ancestry cohorts and transfer imperfectly to others. Age matters tremendously, and the genotype is one input among many rather than a switch.
An e4/e4 genotype is not a diagnosis - it is a call to attention to particular lifestyle choices to optimize your body to your genotype. Thankfully, the levers that move the needle here are multi-purpose, high-impact opportunities that will benefit you regardless of your genotype. In short, optimizing sleep, ensuring a healthy regimented exercise routine, eating healthy, optimizing certain blood markers and focusing on a joyful social life. Call these the best "medicine" for e4/e4; it could be worse.
What the genotype is
APOE status is read from two positions together, rs429358 and rs7412, because the pair is what determines which isoform a copy carries. The e4/e4 diplotype means both copies are the e4 form. It is flagged as the highest common genetic risk configuration for late-onset Alzheimer's disease among people of European descent PMID 9343467. Neither SNP alone tells you your isoform; both have to be read to resolve e2, e3, and e4 correctly (which the Varia Genome Scanner does reliably well).
What the literature reports
Meta-analytic data pooling clinic and autopsy-based studies report an odds ratio of roughly 14.9 for Alzheimer's disease in e4/e4 carriers compared with the e3/e3 reference, in Caucasian cohorts PMID 9343467. Earlier family-based work described a gene-dose pattern, with risk rising as the number of e4 copies goes from zero to one to two PMID 8346443.
Two things are worth holding together here. The relative risk is genuinely high, which is why this genotype gets the attention it does. And an odds ratio is a statement about groups: it describes how much more common the genotype is among people with the disease than among people without it, not a personal probability that you will develop it. The same literature that establishes the association also documents people with e4/e4 who reach old age without dementia.
What Varia does with this variant
Varia reads both rs429358 and rs7412 from your raw DNA file and resolves your full APOE diplotype locally, on your own device. The result appears under Brain and Cognition with the sourced effect language and the linked, peer-reviewed citations from the curated catalog. Varia describes what the published evidence reports. Our mission is to prepare you with the facts as they stand on the matter. We are not going to sugarcoat and we are not going to fear-monger. Our intention is to empower people with transparency about their own body.
Questions and answers
Does e4/e4 mean I will develop Alzheimer's disease?
No. The genotype is associated with higher population-average risk in published studies, not certainty for any individual. Many e4/e4 carriers never develop the disease, and age, ancestry, and other factors all matter PMID 9343467.
Why does Varia read two positions for one result?
Because the APOE isoform is defined by the combination. Neither rs429358 nor rs7412 on its own determines whether a copy is e2, e3, or e4, so Varia reads both to resolve the diplotype correctly.
Is the risk the same across ancestries?
No. The strongest effect estimates come from European-ancestry cohorts, and the association is documented to vary across populations. Varia surfaces the published figures and notes that they do not transfer as fixed constants.
The short version
What is established: e4/e4 is the most strongly associated common genetic configuration for late-onset Alzheimer's disease in the published literature, with a large relative risk versus e3/e3 and a gene-dose pattern PMID 9343467 PMID 8346443.
What is not established: that the genotype determines any individual's outcome. It raises population-level risk; it does not settle a personal fate, and the figures come largely from European-ancestry cohorts.
To check your own APOE result and read the cited, peer-reviewed evidence behind it, use the Varia Genome Scanner. It reads your raw DNA file in your browser and checks it for rs429358 and rs7412 along with the rest of the catalog. Array files like 23andMe and AncestryDNA cover most catalog variants but not all, so the scan tells you whether yours are included.